CAAR T Cells Targeting Anti-PLA2R B Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for primary membranous nephropathy lack specificity for autoreactive B cells producing anti-PLA2R antibodies, leading to risks of life-threatening infections and disease relapse after kidney transplantation.
Innovation Solution
Development of a chimeric autoantibody receptor (CAAR) specific for the phospholipase A2 receptor (PLA2R) that targets and kills anti-PLA2R B cells, using genetically modified T cells expressing a PLA2R extracellular domain, a transmembrane domain, and an intracellular costimulatory or signaling domain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (alkylating agents, calcineurin inhibitors, rituximab) are used to treat primary membranous nephropathy, then proteinuria can be reduced, but the treatment lacks specificity for autoreactive B cells producing anti-PLA2R antibodies, leading to life-threatening infections and disease relapse
Solution Approach 1:
The patent introduces a chimeric autoantibody receptor (CAAR) as an intermediary that specifically recognizes and binds to anti-PLA2R autoantibodies on autoreactive B cells. This CAAR acts as a mediator between the therapeutic agent and the target B cells, enabling precise identification and elimination of pathogenic cells without affecting healthy B cells, thus resolving the contradiction between treatment effectiveness and infection/relapse risk
Solution Approach 2:
The patent extracts and isolates the specific target (anti-PLA2R autoantibodies) from the complex immune system, using the CAAR to selectively bind and eliminate only the pathogenic B cells producing these autoantibodies. This extraction approach allows precise targeting of the harmful subset of B cells while preserving the beneficial B cell population, thereby reducing infections and relapse risk while maintaining treatment effectiveness
2Productivity
If non-specific immunosuppressive treatments are administered, then proteinuria decreases, but specificity for autoreactive B cells is lost, causing healthy B cells to be affected and increasing infection risk
Solution Approach 1:
The patent applies local quality by endowing the CAAR with specific local recognition properties that allow it to distinguish anti-PLA2R autoantibodies from other antibodies. The CAAR's extracellular domain is specifically designed to bind only to the target autoantibodies, creating a localized specificity at the binding interface while maintaining overall B cell targeting capability, thus achieving both proteinuria reduction and treatment specificity
3Reliability
If alkylating agents or calcineurin inhibitors are used as first-line therapy, then severe primary membranous nephropathy can be treated, but relapse occurs after kidney transplantation due to lack of disease-specific targeting
Solution Approach 1:
The CAAR serves as a disease-specific intermediary that continuously identifies and eliminates autoreactive B cells producing anti-PLA2R autoantibodies. This mediator ensures long-term disease control by maintaining suppression of pathogenic B cells even after kidney transplantation, preventing relapse that occurs with conventional immunosuppressive therapies
Solution Approach 2:
The patent implements a feedback mechanism where the CAAR continuously monitors for the presence of anti-PLA2R autoantibodies and actively eliminates B cells producing them. This feedback loop ensures sustained disease control and prevents relapse by dynamically responding to any resurgence of autoreactive B cells, providing long-term remission beyond what conventional therapies achieve
Data Source
AI summary
The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified cell, e.g., a genetically modified T cell, expressing a PLA2R-CAAR wherein the expressed CAAR comprises a PLA2R extracellular domain.